Efficacy prediction and molecular mechanism of thyroid hormone levels and multi-target TKI therapy for renal cell carcinoma and hepatocellular carcinoma
{"title":"Efficacy prediction and molecular mechanism of thyroid hormone levels and multi-target TKI therapy for renal cell carcinoma and hepatocellular carcinoma","authors":"Yueqin Sun, Aimin Li, Yue Luo, Zheng-Xiang Song, Xue-Wei Zhuang, Guanqi Dai","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.05.011","DOIUrl":null,"url":null,"abstract":"Hypothyroidism is a common adverse reaction in clinical multi-target tyrosine kinase inhibitor (TKI) and may be used as a predictor of efficacy of TKI drugs. Studies show that hypothyroidism is significantly associated with good prognosis in patients with renal cell carcinoma treated with multi-target TKI, which may be related to inhibition of vascular endothelial growth factor receptor pathway, potential off-target effects and inhibition of cell proliferation. Whereas in the patients with hepatocellular carcinoma who received multi-target TKI therapy, hypothyroidism is an indicator of poor prognosis, which is related to the T3/TR pathway regulating liver cancer growth and invasion. The predictive function and mechanism of thyroid hormone levels in different tumor patients receiving multi-target TKI drugs are different, and further research is still needed. \n \n \nKey words: \nThyroid hormones; Neoplasms; Prognosis; Tyrosine kinase inhibitors","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"27 1","pages":"303-306"},"PeriodicalIF":0.0000,"publicationDate":"2019-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际肿瘤学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.05.011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Hypothyroidism is a common adverse reaction in clinical multi-target tyrosine kinase inhibitor (TKI) and may be used as a predictor of efficacy of TKI drugs. Studies show that hypothyroidism is significantly associated with good prognosis in patients with renal cell carcinoma treated with multi-target TKI, which may be related to inhibition of vascular endothelial growth factor receptor pathway, potential off-target effects and inhibition of cell proliferation. Whereas in the patients with hepatocellular carcinoma who received multi-target TKI therapy, hypothyroidism is an indicator of poor prognosis, which is related to the T3/TR pathway regulating liver cancer growth and invasion. The predictive function and mechanism of thyroid hormone levels in different tumor patients receiving multi-target TKI drugs are different, and further research is still needed.
Key words:
Thyroid hormones; Neoplasms; Prognosis; Tyrosine kinase inhibitors